November 24, 2025

Oral PCSK9 Inhibitor Tied to LDL-C Drop

The oral PCSK9 inhibitor enlicitide decanoate achieved 58% LDL-C reduction in patients with heterozygous familial hypercholesterolemia, offering a potential alternative to injectable therapies.

Conexiant

November 21, 2025

ALD-related HCC mortality surges 

 The findings underscore the urgent need for targeted prevention strategies among high-risk group.

Conexiant

November 21, 2025

Tirzepatide tops semaglutide for cardiometabolic protection in MASLD

The study authors recommend prospective head-to-head trials to validate the findings.

Conexiant

November 21, 2025

Positive trends in chronic HCV mortality 

“DAAs have revolutionized the management of HCV by making it a curable disease.”

Conexiant

November 20, 2025

New score challenges old predictors

"MERAGE has superior performance for predicting return to drinking (RTD) compared to HRAR in AH."

Conexiant

November 13, 2025

Allergies May Increase Surgical Risk

Researchers show that patients with allergies face higher postoperative risks.

Conexiant

November 13, 2025

New AI Model Guides UTI Therapy Decisions

A predictive algorithm presented at AMP 2025 may extend the Guidance UTI workflow by delivering actionable insights before full susceptibility results are available.

Conexiant

November 11, 2025

ED drugs tied to lower gastric cancer risk

Large retrospective study finds 30% reduction in gastric malignancy among men taking erectile dysfunction medications.

Conexiant

November 10, 2025

Gastric microbiome shifts track H pylori virulence

Pathogenic bacterial genotypes correlate with distinct microbial communities; overall α-diversity is unchanged, but virulent strains show greater diversity within subgroups as atrophy progresses

Conexiant